<DOC>
	<DOCNO>NCT01370889</DOCNO>
	<brief_summary>This pilot phase I trial study resveratrol postmenopausal woman high body mass index . Chemoprevention use certain drug keep cancer forming . The use resveratrol may keep cancer form . Studying sample blood urine laboratory postmenopausal woman take resveratrol may help doctor learn effect resveratrol biomarkers .</brief_summary>
	<brief_title>Resveratrol Postmenopausal Women With High Body Mass Index</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine effect pharmacological dos resveratrol serum estradiol level post-menopausal woman high body mass index ( BMI ) . SECONDARY OBJECTIVES : I. Assess effect resveratrol serum estrone , testosterone , sex hormone-binding globulin ( SHBP ) . II . Assess effect resveratrol serum level insulin C-peptide . III . Assess effect resveratrol adipocytokine expression secretion measure serum leptin adiponectin . IV . Assess effect resveratrol inflammatory cytokine measure serum C-reactive protein ( CRP ) . V. Assess effect resveratrol oxidative stress measure urinary 8-isoprostaglandin F2 alpha ( 8-iso-PGF2 alpha ) 8-hydroxydeoxyguanosine ( 8OHdG ) . VI . Assess safety resveratrol intervention measure reported adverse event , complete blood count differential ( CBC/diff ) , comprehensive metabolic panel ( CMP ) , lipid profile . VII . Assess relationship systemic study agent exposure biomarker modulation . OUTLINE : Patients receive resveratrol orally ( PO ) daily ( QD ) 12 week . After completion study therapy , patient follow 2 week</detailed_description>
	<mesh_term>Resveratrol</mesh_term>
	<criteria>Healthy postmenopausal woman body mass index ( BMI ) 25 kg/m^2 great Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ; Karnofsky 70 % Leukocytes &gt; = 3,000/uL Absolute neutrophil count ( ANC ) &gt; = 1,500/uL Platelets &gt; = 100,000/uL Total bilirubin = &lt; 2.0 mg/dL Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) = &lt; 1.5 time upper limit normal ( ULN ) Creatinine = &lt; 1.0 time ULN Ability willingness limit resveratrolcontaining food one serve per day 14 week Negative mammogram negative workup mammographic finding within prior 12 month prior enrollment woman &gt; = 50 year age Ability understand willingness sign write informed consent document Have invasive cancer ( ) within past 5 year except nonmelanoma skin cancer Within 3 month concurrent usage investigational agent History allergic reaction attribute resveratrol Unwilling unable refrain take herbal medicine dietary supplement Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Within 3 month concurrent estrogen progesterone replacement therapy , oral contraceptive , androgen , luteinizing hormonereleasing hormone analog , prolactin inhibitor , antiandrogens ; vaginal estrogen acceptable . Within 3 month concurrent usage tamoxifen , raloxifene , selective estrogenreceptor modulators , aromatase inhibitor Regular usage ( 2 time week ) estrogenic supplement herbal remedy ( e.g. , Remifemin , black cohosh , red clover , dong quai , soy isoflavones , dehydroepiandrosterone [ DHEA ] , flaxseed , diindolylmethane [ DIM ] , genistein , daidzein ) within past 3 month concurrently ; dietary consumption phytoestrogens/isoflavones ( soy , tofu , millet , barley , natto , tempeh , miso , soy milk , soy sauce ) acceptable source concentrate Concurrent use antidiabetic drug : Insulin Sulfonylureas ( e.g. , glipizide , glyburide , glimepiride ) Meglitinides ( e.g. , repaglinide nateglinide ) Biguanides ( e.g. , metformin ) Thiazolidinediones ( e.g. , rosiglitazone pioglitazone ) Alphaglucosidase inhibitor ( e.g. , acarbose miglitol ) Dipeptidyl peptidase4 ( DPP4 ) inhibitor ( e.g. , sitagliptin ) Concurrent use warfarin phenytoin</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>